Premium
FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL
Author(s) -
Kahl B.,
Hamadani M.,
Caimi P.F.,
Reid E.G.,
Havenith K.,
He S.,
Feingold J.M.,
O'Connor O.A.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_33
Subject(s) - medicine , neutropenia , adverse effect , tolerability , nausea , gastroenterology , refractory (planetary science) , oncology , antibody drug conjugate , toxicity , antibody , immunology , physics , astrobiology , monoclonal antibody
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom